A carregar...
Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations
Delayed-release dimethyl fumarate (DMF), also known as gastroresistant DMF, is the most recently approved oral disease-modifying treatment (DMT) for relapsing multiple sclerosis. Two randomized clinical trials (Determination of the Efficacy and Safety of Oral Fumarate in Relapsing–Remitting MS [DEFI...
Na minha lista:
| Publicado no: | Ther Clin Risk Manag |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4780395/ https://ncbi.nlm.nih.gov/pubmed/27042079 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S85099 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|